Drug Profile
Research programme: vaccines - Bharat Biotech
Alternative Names: Malaria vaccine - Bharat Biotech; Methicillin-resistant Staphylococcus aureus vaccine - Bharat Biotech; Non-typhoidal salmonella vaccine -Bharat Biotech; NTS conjugate vaccine - Bharat Biotech; Papilloma virus vaccine - Bharat Biotech; Pertussis vaccine - Bharat Biotech; Plasmodium vivax malaria vaccine; PvR II; PvRII/Matrix-M; Tetanus vaccine - Bharat BiotechLatest Information Update: 08 Jun 2022
Price :
$50
*
At a glance
- Originator Bharat Biotech
- Developer Bharat Biotech; Center for Vaccine Development
- Class Bacterial vaccines; Conjugate vaccines; Viral vaccines
- Mechanism of Action Duffy antigen binding protein modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malaria
- No development reported Human papillomavirus infections; Methicillin-resistant Staphylococcus aureus infections; Pertussis; Salmonella infections; Tetanus
Most Recent Events
- 21 May 2022 PvR II is still in preclinical phase for Malaria (Parenteral) in India
- 21 May 2022 University of Oxford plans a phase-II trial for Malaria (In volunteers)in Thailand (Parenteral) in September 2022 (NCT05380388)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in India (Parenteral)